Defilade Capital Management, L.P.

Position in NBIX — Neurocrine Biosciences Inc

CIK 2088557 EMERYVILLE, CA

Back to NBIX Full portfolio

Position in NBIX

as of Mar 31, 2026 · filed May 14, 2026 Compact

Position Value

$27,656,441

New position

Shares Held

209,932

first reported quarter

Ownership

0.209%

of shares outstanding

% of Portfolio

3.88%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2026

1 quarter on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Mar 31, 2026

Defilade Capital Management, L.P. holds $68,855,231 across 3 Drug Manufacturers - Specialty & Generic names. NBIX ranks #1 (40.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	NBIX	Neurocrine Biosciences Inc This page	209,932	$27,656,441
2	ELAN	Elanco Animal Health Inc	931,121	$22,281,725
3	LNTH	Lantheus Holdings, Inc.	249,401	$18,917,065

1 filing row on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$27,656,441	209,932	—	Shares	Sole	2026-05-14
No filing history on record for this holder in this stock.

Defilade Capital Management, L.P.

Position in NBIX

Position in Drug Manufacturers - Specialty & Generic

All Filings in NBIX